Sector News

Stryker Corporation to create hundreds of jobs at new Irish base

March 30, 2015
Life sciences
The Stryker Corporation, one of the world’s leading medical technology firms, is to create hundreds of new jobs with a multi-million euro investment in Cork.
 
The company is to formally announce plans to build a global centre of excellence at Carrigtwohill this week.
 
The firm currently employs around 1,200 people in Ireland including 700 at two IDA sites in Carrigtwohill with a further 500 employed at a factory in Raheen, Limerick.
 
The Irish Examiner reports that the new plant is expected to be built before the end of the year and that it will create hundreds of jobs. Part of the remit of the new plant will be to build hip and knee replacements with 3D laser printing technology.
 
By Paul O’Donoghue
 

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”